Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma.
about
Cancer immunotherapy: the beginning of the end of cancer?Oncolytic virotherapy using herpes simplex virus: how far have we come?Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advancesCombination Approaches with Immune-Checkpoint Blockade in Cancer TherapyTrial Watch-Oncolytic viruses and cancer therapyCancer immunotherapy: Strategies for personalization and combinatorial approaches.The Rapid Emergence of Novel Therapeutics in Advanced Malignant Melanoma.Combination of Plant Virus Nanoparticle-Based in Situ Vaccination with Chemotherapy Potentiates Antitumor Response.The safety of talimogene laherparepvec for the treatment of advanced melanoma.Oncolytic virotherapy for urological cancers.Interaction of molecular alterations with immune response in melanoma.A practical guide to the handling and administration of talimogene laherparepvec in Europe.Therapeutic Cancer Vaccines.Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain.Novel treatment opportunities for sulfur mustard-related cancers: genetic and epigenetic perspectives.Intravenous injections of the oncolytic virus M1 as a novel therapy for muscle-invasive bladder cancer.Combination therapy for cancer with oncolytic virus and checkpoint inhibitor: A mathematical model.Mechanisms regulating T-cell infiltration and activity in solid tumors.Talimogene Laherparepvec: First in Class Oncolytic Virotherapy.The importance of imaging strategies for pre-clinical and clinical in vivo distribution of oncolytic viruses.Talimogene laherparepvec: overview, combination therapy and current practicesOncolytic virus and PD-1/PD-L1 blockade combination therapy
P2860
Q26752277-F2F2DAF2-2FAA-4AA0-93F0-13A11DD6F5F7Q26862461-A2737614-A266-48FA-B432-2634CD46F959Q26863779-D8F847B8-3763-413D-BEC7-77969885A7E6Q28066199-78AC1544-9900-4FA0-9B3A-F901A4AA19C3Q28072347-49D49D11-4495-4C3F-B468-D035E6553D99Q36387028-8302CA73-8B0E-4695-9156-4E6F80632FBCQ38589776-F9946B0B-329E-4BFC-9781-1ACBA3242543Q38708960-3C595328-975A-4C6A-A527-1A2C7FCD8FA9Q38781281-E0864122-C7C2-4691-AB80-99B9C898FD30Q38842126-BE5F32C4-ECB8-4C74-B731-F04FAFD0C16AQ39329609-12263226-BCD2-4B7A-B1D3-D46ABD3A6EE1Q40080717-40656684-1F0D-49D2-8FDF-3BAC2C478AA6Q40728648-37F9B4A0-BFC1-4478-AFC5-C79AD70BD99FQ45854947-9942879A-EE3D-408D-A746-5148402B6FB0Q45873027-ABB4FDD0-84A9-4C10-B69B-01ACB4675061Q49959107-5DB01422-4C0D-45B2-9632-6444AA137252Q50053595-86CE9EB3-FC25-4626-B100-66C926E66E3EQ50089395-576DDF11-0474-47B6-A8C1-8B536B0ED680Q50116255-D3516316-EC18-4E2F-BAAA-1BEE60DFF396Q52594999-562EEC7E-E4B7-4C3B-9DF5-FF47FAA496BAQ56894524-8E62161C-4337-4961-A92A-8CCE7CCE27E8Q57174025-214405DA-ADC4-4765-B0C1-DF4CADA8E03D
P2860
Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma.
@en
type
label
Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma.
@en
prefLabel
Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma.
@en
P2860
P356
P1433
P1476
Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma.
@en
P2093
Douglas B Johnson
Mark C Kelley
P2860
P304
P356
10.2217/IMT.15.35
P50
P577
2015-06-22T00:00:00Z